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 Abstract 
 Pancreatic β-cells play a central role in glucose homeostasis by tightly regulating 
insulin release according to the organism demand. Impairment of β-cell function due to 
hostile environment, such as hyperglycaemia and hyperlipidaemia, or due to autoimmune 
destruction of β-cells results in diabetes onset. Both environmental factors and genetic 
predisposition are known to be involved the development of the disease, but the exact 
mechanisms leading to β-cell dysfunction and death remains to be characterized. Non-
coding RNA molecules, such as microRNAs, have been suggested to be necessary for 
proper β-cell development and function. The present review aims at summarizing the 
most recent findings about the role of non-coding RNAs in the control of β-cell functions 
and their involvement in diabetes. We will also provide a perspective view of the future 
research directions in the field of non-coding RNAs. In particular, we will discuss the 
implications for diabetes research of the discovery of a new communication mechanism 
based on cell-to-cell microRNA transfer. Moreover, we will highlight the emerging 
interconnections between microRNAs and epigenetics and the possible role of long non-
coding RNAs in the control of β-cell activities.   
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Introduction 
Pancreatic β-cells are highly specialized endocrine cells located within the islets of 
Langerhans. Insulin, the hormone released by these cells, plays a central role in the 
control of carbohydrate and lipid metabolism in the human body. Secretion of 
inappropriate amounts of insulin, due to β-cell dysfunction and/or loss, leads to different 
forms of diabetes mellitus. Type 1 diabetes (T1D), representing about 5-10% of the cases, 
results from the autoimmune destruction of β-cells [1]. Type 2 diabetes (T2D), the most 
common form of the disease (about 90% of the cases), is initiated by a diminished 
sensitivity of insulin target tissues often linked to obesity [2]. This insulin resistance state 
is normally compensated by an increased secretory activity of β-cells and by expansion 
of the functional β-cell mass. However, in genetically predisposed individuals this 
adaptive mechanism fails to compensate the increased insulin needs leading to 
insufficient hormone supply and post-prandial hyperglycemia. The resulting exposure of 
β-cells to chronically elevated concentrations of glucose, free fatty acids and cytokines 
has a deleterious impact on their functions, leading to defective insulin secretion and, 
eventually, partial loss of the cells by apoptosis. This combination of events culminates in 
the manifestation of T2D. 
In the last two decades, a large number of studies attempted to determine the 
causes of β-cell dysfunction in the initial phases of T1D and T2D focusing mainly on the 
role of transcription factors. Although activation of specific transcription factors is 
certainly contributing to gene expression changes associated with β-cell failure, recent 
studies reported the existence in mammalian cells of an entirely new class of gene 
regulatory molecules. Indeed, high-sequencing throughput techniques unveiled the 
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existence of thousands of non-coding RNA molecules generated from independent 
transcription units located outside of protein-coding genes or produced from intronic 
regions [3,4]. These non-coding RNAs fall into two major categories: small non-coding 
RNAs, of which microRNAs (miRNAs) represent the best characterized class, and long 
non-coding RNAs (LncRNAs). The function of small and long non-coding RNAs is only 
beginning to emerge but there is already strong evidence of their involvement in the 
development of several diseases, including diabetes. This review aims to summarize the 
most recent findings about the role of non-coding RNAs in the control of β-cell functions 





Biogenesis and mode of action 
MiRNAs are small non-coding RNA molecules which function as specific regulators of 
gene expression [3]. So far, more than 1500 predicted miRNA precursors, leading to up 
to 2154 mature miRNAs, have been identified in the human genome 
(www.miRbase.org). Most mammalian miRNAs are transcribed by RNA polymerase II 
as primary molecules (pri-miRNAs) containing characteristic stem-loop structures [5]. 
Primary transcripts are thereafter cleaved by the RNase III-type enzyme Drosha 
associated with DGCR8/Pasha proteins to produce hairpin-structured precursors of 
around 70 nucleotides, called pre-miRNAs. Then, pre-miRNAs are transported by the 
export receptor exportin-5 to the cytoplasm, where they are cleaved by the 
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endoribonuclease Dicer to generate an imperfect miRNA/miRNA* duplex of 
approximately 22 nucleotides. Subsequent to Dicer cleavage, the guide miRNA strand of 
the duplex is loaded on an Argonaute protein (mainly Ago1 or Ago2) and incorporated 
into the RNA-induced silencing complex (RISC). The passenger miRNA* strand (also 
called, miRNA-3p) can be degraded or also loaded on Ago2 to act as a functional 
miRNA. Finally, the RISC complex guided by the mature miRNA binds to 
complementary sites within the 3’untranslated region (3’UTR) of the target messenger 
RNA (mRNA), leading to translational inhibition and/or transcript degradation [3]. This 
canonical miRNA biogenesis pathway generates most of the miRNAs expressed in 
mammals. However, other atypical pathways have been described recently [6,7].  
Computational algorithms predict that most of the human protein-coding genes 
contain miRNA-binding sites within their 3’UTR [8]. A single miRNA has the potential 
to bind hundreds of mRNA targets while, conversely, a single 3’UTR region can be 
regulated by several different miRNAs [9]. The ability of miRNAs to associate with the 
3’UTR region of target mRNAs and to repress their translation is mainly determined by 
the so-called seed sequence, which is complementary to residues 2-8 in the 5’ region of 
the miRNA [3,9]. The most popular computational algorithms, predict potential miRNA 
target genes, based on the complementarities between the sequences of the target and the 
miRNA with emphasis on perfect base-pairing of the seed region and on sequence 
conservation between different animal species. Recently, however, alternative target 
recognition mechanisms involving G-bulge sites at positions 5-6 have been shown to 




During their biogenesis, pre-miRNAs are exported into the cytoplasm where they are 
processed into mature and active single-stranded miRNAs. Therefore, mature miRNAs 
are generally considered to be cytosolic molecules. Nonetheless, growing evidence 
suggests that some of the mature miRNAs as well as components of the machinery 
mediating miRNA function are localized into other cellular compartments such as the 
nucleus or the mitochondria (Fig.1). The presence of mature miRNAs in isolated nuclei 
has been confirmed in different cell types using fractionation protocols followed by 
microarray analysis [11]. Detailed investigations revealed differential expression of 
miRNAs within the nucleolus, the nucleoplasm or the cytoplasm of rat myoblasts [12]. 
The homology of some nucleolar miRNAs with small nucleolar-specific RNAs suggests 
a common biosynthetic route, whereas other nucleolar miRNAs are probably transported 
there in order to be modified or to play specific roles. Recent studies identified the 
mitochondria as a new localization site for miRNAs. Both precursor and mature forms of 
miRNAs were detected in mitochondria isolated from human skeletal muscle cells or 
HeLa cells [13,14]. However, the origin of these miRNAs, i.e. whether they are produced 
in the nucleus or directly inside the mitochondria, and if they accomplish specific 
functions justifying their localization in this organelle remain to be determined. The 
cellular compartment in which miRNAs are preferentially located may reflect their 
functions and/or fates. These data suggest the involvement of miRNAs in new regulatory 
processes, possibly going beyond their known activities as translational inhibitors.  
Dynamic structures such as stress granules (SG) or processing bodies (PB) are 
other compartments in which miRNAs can accumulate (Fig.1). Ago2, which is part of the 
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RISC machinery, has been shown to translocate to both SG and PB in case of cellular 
stress. Leung et al., demonstrated that in HeLa cells stress induction by incubation with a 
translation initiation inhibitor leads to accumulation of miRNAs and Ago2 in SG [15]. 
Detzer et al. confirmed the translocation of Ago2 to SG in response to stress and the 
decrease in miRNA activity, but did not observe relocalization of miRNAs [16]. These 
reports support the hypothesis that miRNA distribution in specific cellular compartments 
such as cytosol, nucleus and mitochondria might be influenced by environmental cues. 
During the initial stages of T1D and T2D, β-cells are submitted to diverse types of stress 
stimuli causing dysfunction and death. It is tempting to hypothesize that these stressful 
conditions may be associated with modifications in miRNA localization potentially 
resulting in alterations in β-cell function. However, this appealing scenario remains to be 
proven because no information is yet available about redistribution of miRNAs in β-cells 
or in insulin target tissues under physiological or diabetic conditions.  
 
Circulating miRNAs as diabetes biomarkers 
The role of miRNAs may go beyond their function inside the cells, since these non-
coding RNAs are present in stable and active forms also in extracellular fluids, such as 
blood [17]. The analysis of circulating miRNAs revealed that they predominantly 
originate from neighbouring tissues and from cells lining the vessel walls rather than 
from blood cells themselves [18]. This discovery boosted the interest in circulating 
miRNAs as potential disease biomarkers and clinical indicators. In line with this idea, 
Zampetaki and colleagues performed miRNA profiling in blood samples from a 
prospective study including 800 individuals and identified a characteristic plasma 
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signature involving changes in five miRNAs in the samples of T2D subjects [19]. 
Interestingly, the level of these miRNAs was already modified years before the 
development of the disease. If confirmed, this miRNA signature might represent a good 
predictor enabling the identification of individuals at risk of developing T2D [20]. 
Nonetheless, the use of plasma miRNAs as biomarkers for diabetes risk needs to be 
evaluated with caution. Indeed, a recent study reported up-regulation of seven diabetes-
related miRNAs in blood samples of newly diagnosed T2D patients compared to T2D-
susceptible subjects with normal glucose tolerance [21]. However, miRNA profiles of 
normal glucose tolerant patients were similar to those of pre-diabetic individuals, 
suggesting that alone this group of miRNAs is not sufficient for the prognosis of diabetes 
onset. This result is probably due to the fact that the authors tested only miRNAs known 
to be involved in β-cell dysfunction and in the pathogenesis of T2D. MiRNA changes 
taking place in dysfunctional β-cells or insulin target tissues may not necessarily be 
reflected in modifications in the blood miRNA profile and vice-versa. Thus, blood 
miRNA data can yield different and maybe complementary information to measurements 
at the cellular/tissue level.  
 
Role of miRNAs in the regulation of pancreatic β-cell functions 
Evidence for the role of miRNAs in pancreatic islet development has been provided by 
the generation of pancreas–specific Dicer1 knockout mice. These mice display impaired 
formation of the endocrine pancreas, with severe reduction in the amount of β-cells, 
suggesting that miRNA expression is essential for proper pancreatic development [22]. 
Similarly, Kalis et al. found that β-cell specific deletion of Dicer1 did not affect fetal or 
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neonatal development of insulin-secreting cells, but resulted in progressive 
hyperglycemia leading to adulthood-onset diabetes mellitus [23]. Moreover, in vitro 
analysis of pancreatic islets from Dicer1 β-cell specific null mice revealed impaired 
insulin gene expression, with concomitant decrease in insulin secretion, altered islet 
morphology, and reduced β-cell mass, preceding the hyperglycemic state. Similar results 
were confirmed in an independent study where Dicer1 expression was diminished in 
adult β-cells, resulting in a drastic reduction in insulin content and diabetes development 
but without changes in β-cell architecture [24]. Taken together, these findings point to a 
central role of the miRNA network in pancreatic development and in the achievement of 
specialized β-cell functions.  
A series of studies provided further clarifications about the role of specific 
miRNAs in β-cell development (Table 1). A group of four different miRNAs (miR-7, 
miR-9, miR-375 and miR-376) were reported to be highly expressed during human 
pancreatic islet development [25]. In addition, miR-375 was shown to be involved in the 
development of endocrine pancreas and proper islet formation in two different animal 
models [26,27]. Interestingly, miR-375 is among a subset of miRNAs particularly 
enriched in pancreatic islet cells [28] and its expression is under the control of Pdx1 and 
NeuroD1, two critical transcription factors for the development of the endocrine pancreas 
[29]. Mice lacking miR-375 are hyperglycemic and have elevated plasma glucagon levels 
in both fed and fasting states. This phenotype correlates with an increase in α-cell 
number and a decrease in β-cell mass leading to a profound imbalance in the cellular 
composition of the endocrine pancreas. In addition, genetic deletion of miR-375 in ob/ob 
mice, an insulin resistance model characterized by β-cell mass expansion, led to 
 9 
impairment in β-cell proliferation capacity resulting in a severe diabetic state [27]. 
Finally, Zhao et al. observed a positive correlation between miR-375 expression in T2D 
patients with extended amyloid formation and reduced β-cell mass [30]. Other groups 
investigated the role of miR-375 expression in mature β-cells. In addition to its positive 
effect on the β-cell mass, miR-375 has a negative impact glucose-induced insulin 
secretion by reducing the level of myotrophin, a protein thought to be involved in insulin-
granule fusion, and to regulate insulin gene expression by targeting PDK1 and the 
phosphoinositol-3-kinase pathway [28,31]. Therefore, miR-375 is a key regulator of 
several β-cell features, such as insulin expression and secretion, proliferation and 
adaptation to insulin resistance.   
Other miRNAs have also been investigated for their implication in pancreas 
development (Table 1). Baroukh et al. observed an up-regulation of miR-124a during 
pancreatic developmental stages where it modulates diverse intracellular pathways via the 
regulation, both directly and indirectly, of Foxa2, a transcription factor driving the 
expression of Pdx-1, which is essential for β-cell differentiation [32]. MiR-7, another 
miRNA highly expressed in human pancreatic fetal and adult endocrine cells [25] 
displayed changes in expression during mice pancreatic development. Inhibition of miR-
7 at early developmental stages affected the number of β–cells, impaired insulin 
production and resulted in glucose intolerance in the post-natal period [33].  
Taken together, these results indicate that a fine-tuning of the expression of 
miRNAs takes place already at the early stages of pancreas development and that these 
variations of expression drive major changes in the level of key genes regulating β-cell 
generation and differentiation.  
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Beside their role in endocrine pancreas development, miRNAs have been shown 
to be involved in the control of adult β-cell mass and function (Table 1).  Upon 
overexpression in the insulin-secreting β-cell line INS-1E, miR-9 reduced insulin 
secretion triggered by glucose or potassium by targeting Onecut-2. This transcription 
factor negatively regulates the level of granuphilin, a synaptotagmin-like protein that 
functions as a brake for insulin-secreting granules [34]. Interestingly, miR-9 expression is 
increased soon after glucose-induced insulin secretion, leading to direct targeting and 
inhibition of Sirt1, known to play a role during insulin release [35]. MiR-124a, has been 
reported to negatively impact on glucose-induced insulin secretion by inducing the 
expression of SNAP25, Rab3A and synapsin-1A, and by decreasing those of Rab27A and 
Noc2 [36]. Overexpression of this miRNA enhanced exocytosis under basal conditions 
while it inhibited glucose-induced hormone release [36]. Two other miRNAs, miR-29a 
and b, are of particular interest for proper β-cell function because they are involved in the 
silencing of monocarboxylate transporter Mct1, which is necessary for proper coupling of 
glucose metabolism with insulin secretion [37]. Glucose-stimulated hormone release is 
also reduced in human and mouse islets where miR-33a is overexpressed leading to a 
decrease in the cholesterol transporter ABCA1 expression and a consequent accumulation 
of cholesterol [38]. Whether miR-33a regulates insulin release via modulation of 
cholesterol levels and/or by targeting key enzymes implicated in fatty acid metabolism, 
such as CPT-1, AMPKα and Sirt6 [39] remains to be investigated. Finally, mice 
specifically lacking let-7 in the pancreas display an impairment in glucose-induced 
insulin secretion [40]. 
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So far most of the papers reporting changes in insulin release elicited by miRNAs 
were carried out in vitro. Moreover, they often relied on miRNA overexpression and, 
although in some cases the level of the non-coding RNAs was calibrated to that observed 
in other cell types, non-specific off-target effects cannot be excluded. Thus, 
complementary studies, in particular using in vivo animal models, will be necessary to 
confirm the regulation of insulin secretion in response to glucose and other secretagogues 
and precisely define their mode of action.  
Variations in miRNA expression have been observed upon prolonged exposure of 
pancreatic β-cells to pathophysiological conditions such as hyperglycemia and/or 
elevated free fatty acids which lead to β-cell dysfunction and death [2]. Glucose drives 
important changes in miRNA expression, as observed in Goto-Kakizaki (GK) rats, a 
model of glucose-impaired insulin secretion characteristic of T2D. A group of miRNAs is 
indeed differentially expressed upon exposure of GK pancreatic islets to a hyperglycemic 
environment. Among these, miR-335 has been demonstrated to target the mRNA 
encoding a member of the SNARE complex implicated in insulin secretion [41]. In 
another study performed in the β-cell line MIN6B1 high glucose exposure led to changes 
in the expression of several miRNAs and one of them, miR-30d, was found to modulate 
insulin gene transcription [42]. Similarly, variation in miR-15a expression in mouse islets 
in response to acute or long-term incubation at high glucose correlated with insulin 
mRNA levels. The regulation of insulin biosynthesis by miR-15a was confirmed in MIN6 
cells using miR-15a mimics and a miR-15a inhibitor. The exact mechanism remains to be 
demonstrated but the authors suggested that UCP2, directly targeted by miR-15a, could 
be involved [43]. In another study performed in human islets, miR-146 was found to be 
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reduced upon prolonged exposure to elevated glucose, while the expression of miR-133a 
was enhanced by hyperglycemia, resulting in a decrease in insulin biosynthesis via the 
targeting of PTB, a protein required for insulin mRNA stability [44]. Also miR-375 was 
reported to be negatively regulated by high levels of glucose, probably via a feedback 
loop, since elevated levels of this miRNA attenuate insulin gene transcription by 
targeting PDK1 [31]. Yet not influenced by glucose, another group of miRNAs including 
miR-24, miR-26, miR-148 and miR-182 have been recently identified as positive 
regulators of insulin production through the inhibition of transcriptional repressors [24].  
Several miRNAs have also been reported to display expression changes under 
lipotoxic conditions. The levels of miR-34a and miR-146 increase in presence of 
palmitate and their overexpression is associated with β-cell apoptosis and, in case of 
miR-34a, to impaired insulin secretion. Silencing of these two miRNAs was sufficient to 
attenuate apoptosis induced by palmitate exposure but could not restore normal insulin 
release [45]. MiR-34a along with miR-146a/b and miR-21 are also up-regulated in β-cells 
exposed to cytokines [46]. VAMP2 and Rab3a, whose levels are decreased upon IL-1β 
exposure, are targeted by miR-34a and miR-21, correlating with impaired glucose-
induced insulin secretion. MiR-146a overexpression did not affect hormone release but 
increased β-cell apoptosis as was the case for miR-34a. Down-regulation of miR-21, 
miR-34a and miR-146a in MIN6 cells using antagomirs was able to restore insulin 
release in the presence of IL-1β and, in the case of miR-34a and miR-146, to protect the 
cells from cytokine-induced apoptosis [46]. Concerning miR-21, activation of a NF-
κB/miR-21/PDCD4 signaling cascade in NOD mice was proposed to counteract β-cell 
death observed at early stages of T1D diabetes. Indeed, miR-21 induction is able to 
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directly target and reduce the level of PDCD4, which is known to sensitize β-cells to 
cytokine-induced apoptosis [47]. Recently, microarray profiling revealed that the 
establishment of prediabetic insulitis in NOD mice is associated with an increase in the 
expression of miR-29 family members. Overexpression of these miRNAs in primary β-
cells led to changes in the expression of key genes involved in exocytosis and cell 
survival with consequent defects in glucose-induced in insulin secretion and sensitization 
toward apoptosis [48]. 
The studies described above clearly demonstrate that proper miRNA expression is 
crucial for β-cell development, survival and function. The miRNA field is still at its 
infancy and future investigations will probably permit to precisely appreciate the 
relevance of miRNAs in β-cell biology and in the development of both T1D and T2D. 
 
Future research directions in the non-coding RNA field 
 
Horizontal miRNA transfer as a novel cell-to-cell communication mechanism 
Beside their potential value as disease biomarkers, plasmatic miRNAs may represent a 
new class of cell-to-cell communication molecules. Indeed, circulating miRNAs can be 
taken up by recipient cells where they have the potential to influence gene expression 
[49]. The precise source of circulating miRNAs is not known yet, but they have been 
proposed to originate from: passive leakage from broken cells, active secretion via 
microvesicles or active secretion through an RNA-binding protein-dependant pathway 
(Fig.2). Moreover, a recent study presented evidence that miRNAs can also associate 
with high-density lipoproteins (HDL) and to be delivered to recipient cells with 
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functional targeting capabilities [50]. Interestingly, an important fraction of circulating 
miRNAs is associated with Ago2 [51,52]. Upon in depth analysis of the miRNAs 
transported in the human plasma, the majority of the miRNAs was found to co-purify 
with Ago2 ribonucleoprotein complexes, although some of them, such as for instance 
miR-142-3p, were predominantly associated with microvesicles. There is strong evidence 
that miRNAs enclosed in microvesicles, such as exosomes, can be efficiently taken up in 
active form by recipient cells [53], but the capacity of circulating Ago2/miRNA 
complexes to enter the cells remains to be demonstrated. More studies will be necessary 
to elucidate the physiological meaning and the functional differences between circulating 
miRNAs associated with proteins and those transported in microvesicles. So far, no data 
are available regarding the physiological impact of circulating miRNAs on the regulation 
of β-cell functions. 
As many other cell types, there is evidence indicating that β-cells are able to 
release microvesicles with a potential effect on neighbouring cells. The release of 
miRNA-containing vesicles is a process that can be regulated by different factors 
including a rise in cytosolic free calcium, sphingomyelinase 2, a protein involved in 
ceramide biosynthesis and Rab27A, a GTPase belonging to the insulin secretory 
machinery [53-55]. Therefore, it is tempting to speculate that the release of miRNA-
containing vesicles from β-cells may be affected by hormones, nutrients, stress factors or 
inflammation. In a recent study, Sheng and collaborators investigated the capability of 
exosomes isolated from MIN6 cells to stimulate an autoimmune response in NOD mice. 
They found that MIN6-derived exosomes contain diabetes-associated islet autoantigens 
and stimulate pro-inflammatory cytokine secretion from T cells, leading to islet 
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inflammation. Furthermore, injection of MIN6-derived exosomes in the diabetes-resistant 
mouse strain NOR accelerated insulitis development. This study demonstrates that β-cell 
exosomes can trigger an auto-immune reaction and favour the attack of pancreatic islets 
by T cells, resulting in increased diabetes susceptibility [56]. Since exosomes released by 
cancer cell lines can be different from those secreted by non-transformed cells [55], these 
findings remain to be confirmed using exosomes derived from primary pancreatic islets. 
According to this novel cell-to-cell communication mode, we can assume that 
exosomes released by β-cells contain miRNAs potentially acting on neighbouring 
immune cells or endocrine cells to either stimulate adaptation processes or regulate the β-
cell fate. Transfer of miRNAs in the opposite direction, i.e. via exosomes secreted by 
immune cells and taken up by β-cells, may also have relevant physiopathological 
implications. Future studies should investigate the influence of horizontal miRNA 
transfer on 1) the interaction between pancreatic islet endocrine cells, including α-, β-, δ-, 
PP- and ε-cells, 2) the cross-talk between β-cells, 3) the autoimmune attack of pancreatic 
β-cells in case of T1D and 4) β-cell failure in case of T2D.  
Another potential mechanism of cell-to-cell miRNA transfer so far poorly 
investigated occurs through gap junctions (Fig.2). This process has been reported to occur 
between bone marrow cells and breast cancer cells, resulting in cell cycle quiescence of 
the recipient cells [57]. The potential role of miRNA exchange through gap junctions 
deserves to be studied also in insulin-secreting cells since gap junction communication is 
known to be essential for β-cell functionality. Indeed, inhibition of Connexin 36, a major 
gap junction component in β-cells, induces β-cell death in genetically modified mice, 
while its overexpression protects them against apoptosis [58]. Hence, the investigation of 
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gap-junction mediated miRNA transfer could lead to the identification of novel 
regulatory mechanisms influencing islet cell functions.  
 
Epigenetic regulation of miRNA expression 
It is now well accepted that miRNAs are necessary for proper β-cell development 
and function. Less understood are the mechanisms regulating miRNA expression under 
normal and pathophysiological conditions. MiRNAs can be spatially and temporally 
regulated since they are generally transcribed by Polymerase II [5]. An emerging concept 
suggests that miRNA expression could be regulated by epigenetic modifications [59]. 
Epigenetics is defined as heritable changes in gene expression caused by mechanisms that 
do not affect the DNA sequence itself and is seen as the interface between genetic and 
environmental factors. The two most widely studied epigenetic mechanisms are DNA 
methylation and histone modifications which are known to be crucial for proper control 
of gene expression [59].  
 DNA methylation occurs mainly in sequences enriched in CpG dinucleotides, so 
called CpG islands, and is achieved by the addition of a methyl group to the 5 position of 
a cytosine ring. CpG islands are mainly located in the proximal region of promoters and 
are underrepresented in the rest of the genome. Methylation of CpG islands is generally 
associated with gene silencing whereas hypomethylation is linked to hyperactivation of 
gene expression. Histone modifications refer to post-transcriptional changes of the 
amino-terminal tails of histone subunits. Some histone modifications, such as acetylation, 
are labile and associated with gene activation, and others, such as methylation, are stable 
and lead to gene inactivation [59].   
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Epigenetics, in the context of diabetes, provides an attractive explanation to 
reconcile the discordance of monozygotic twins and the interindividual variations in 
disease severity, and also, to highlight the impact of environmental factors on gene 
expression. Inappropriate DNA methylation is starting to be investigated in the 
pathophysiology of diabetes in human. The promoter of PPARGC1A, a master regulator 
of mitochondrial genes, was found to be hypermethylated in islets of T2D donors [60]. 
Moreover, two recent large-scale studies suggested a link between aberrant DNA 
methylation and pathological diabetic conditions [61,62]. Zhao et al. [62] observed a 
positive correlation between insulin resistance and global DNA methylation of leukocytes 
in blood samples from 84 monozygotic twin donors, and Volkmar et al. [61] profiled 
several DNA methylation changes in promoter region of different genes in pancreatic 
islets of T2D patients compared to healthy donors. Further studies are needed to elucidate 
the role of global and islet-specific DNA methylation in the development of T2D 
pathogenesis. A genome wide-map of four histone modifications associated with gene 
activation (H3K4me1, H3K4me2 and H3K4me3) or repression (H3K27me3) in human 
pancreatic islets was created by Bhandare and colleagues [63]. The pattern of histone 
modifications observed in human islets is complex and difficult to interpret. The 
promoter sequence of Pdx1 and MafA, two major transcription factors in β-cells, are 
highly occupied by modified histone, whereas low levels of histone modifications were 
present at the insulin and glucagon promoter. Furthermore, developmental genes, like 
HOX genes and neuronal transcription factors, showed bivalent histone marks in 
concordance with their close regulation during pancreas development and their silencing 
in adulthood. Further studies are needed to fully understand the purpose of these marks. 
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However, the work of Bandhare and colleagues provide a starting point to study the 
impact of environmental factors on histone modifications and gene expression. Finally, 
another important aspect of epigenetic modifications is that epigenetic marks can occur 
during embryogenesis or early in life. The intrauterine environment and the maternal 
nutrition are known to play an important role in the susceptibility of individuals to 
metabolic disease and diabetes in later life [64,65].  
The regulation of miRNA expression by epigenetic mechanisms has been first 
studied in cancer cells. Several miRNAs have been identified to be epigenetically 
modified [66]. For instance, the expression levels of miR-9 family, miR-34b/c, miR-
124a, miR-127 and miR-148a, have been shown to be deregulated in cancer cells by 
hypo- or hypermethylation of CpG islands located upstream of the mature microRNA 
[59,67-69]. Weber et al. estimated that more than 50% of human miRNA genes represent 
candidate targets to DNA methylation, which is at least one order of magnitude higher 
than protein-coding genes [70]. Epigenetic regulation of miRNAs had also been studied 
in human embryonic stem cells (hESC). Using undifferentiated hESC line HS181 and 
cancer cell lines SIHN-011B and IGR37, Iliou et al. showed that tumor suppressor 
miRNA genes that undergo de novo hypermethylation in cancer cells are enriched in 
bivalent histone marks in embryonic stem cells [67]. These results emphasize the close 
relationship between DNA methylation and histone modifications in the regulation of 
gene expression. They also provide evidences supporting the idea that abnormal 
regulation of specific genes that are pre-marked during embryonic development, can lead 
to pathogenesis during adulthood. 
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To our knowledge, the epigenetic regulation of miRNA genes in β-cells has not been 
investigated so far, but represents a promising field to uncover new mechanisms leading 
to β-cell dysfunction in diabetic conditions. 
 
Role of long non-coding RNAs in β-cells 
LncRNAs are a new class of transcripts which are commonly grouped based on the fact 
that their sequence is equal or longer than 200 nucleotides and contrary to protein coding 
genes, they have poor or no protein-coding potential [71]. LncRNAs are often spliced, 
may be polyadenylated and can be subdivided into large intergenic non-coding RNAs 
(lincRNAs) and those that are sense, antisense, intronic or overlapping with protein 
coding genes [72]. Unlike miRNAs, which act through specific base pair recognition 
mechanisms to modulate the expression of their target genes [3,9], LncRNAs have been 
involved in diverse gene-regulatory mechanisms such as transcription, translation, 
imprinting, genome rearrangement, chromatin modification and other important functions 
such as nuclear factor trafficking and protein degradation [4,73]. Their molecular 
mechanisms can be grouped into four major classes: signals, decoys, guides and scaffolds 
[4]. These groups are not mutually exclusive and most LncRNAs can exert more than one 
function. As LncRNA expression is under tight transcriptional control, most of them can 
be used as molecular signatures for specific processes and are therefore classified as 
signals. LncRNAs acting as decoys directly bind and sequester proteins and presumably 
act by inhibiting their action. LncRNAs act as guides when they direct the localization of 
protein complexes to specific targets and finally, LncRNAs can act as scaffolds by 
serving as platforms upon which multiple molecular components can be assembled. 
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Another interesting function of LncRNA is the capacity of binding to miRNA and 
function as competing endogenous RNAs (ceRNA) [74]. ceRNAs compete for miRNAs 
and regulate their distribution on their target genes. Cesana et al. [75] identified a new 
LncRNA, linc-MD1, which has the ability of regulating muscle differentiation by 
targeting miR-133 and miR-135 via a ceRNA mechanism.  
Despite their mode of action, which remains partly unknown, LncRNAs have 
been involved in many different processes such as stem cell differentiation, modulation 
of apoptosis and invasion and marker of cell fate [76]. Cabili et al.[77] recently showed 
that LncRNAs exhibit greater tissue specificity than protein coding genes. This group 
analyzed approximately 8000 lincRNAs in 24 different tissues and cell types and 
demonstrated that 78% of them were tissue specific, in comparison with only 19% of 
protein coding genes. This tissue specificity is an integral index/component of their 
critical regulatory functionality.  
LncRNAs are not only tissue specific but they can also localize in different subcellular 
compartments, including the nucleus, cell body and in specific foci of adult cerebellar 
purkinje cells [78]. Moreover, their expression can be so specific that the lncRNA 
Gomafu has been found to localize in regions of the nucleus that are different from any 
other nuclear compartment identified by known markers [79].  
Given their wide variety of functions, LncRNAs and their specific patterns of expression 
it is not surprising that their dysregulation has been implicated in many human diseases 
including different forms of cancers and neurodegenerative diseases [73]. In some cases, 
the mechanism giving rise to the disease has been identified. For example, five different 
LncRNAs were found to bind and inhibit the action of PSF, a protein involved in the 
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silencing of the proto-oncogene GAGE6 [27]. For other lncRNAs, specific targets have 
yet to be identified. This is the case of MALAT1, a lncRNA which expression is three 
times higher in metastasizing early-stage non-small cell lung cancer versus non-
metastasizing tumors [80].  
Other lncRNAs involved in diseases are BACE1-AS and ANRIL. BACE1-AS is an 
antisense lncRNA capable of regulating the expression of BACE1, a gene coding for an 
enzyme involved in the production of amyloid β-peptide. The accumulation of this 
protein has been implicated in many neurological disorders and elevated levels of both 
BACE1 and BACE1-AS have been detected in subjects with Alzheimer’s disease [81]. 
ANRIL was firstly identified by a group studying germ line deletions in melanoma-neural 
system tumor family [82]. Interestingly, genome wide association studies (GWAS) 
identified several variants in the intergenic region encompassing ANRIL to be associated 
with several diseases such as coronary heart disease, intracranial aneurysm, many type of 
cancers and type 2 diabetes [83]. ANRIL contribution these pathologies has not yet been 
defined but its action may be mediated through modulation of the expression of the tumor 
suppressor genes at the INK locus (p14, p15, p16). Indeed, ANRIL has been shown to 
interact with both components of the polycomb repressive complexes PCR1 and PCR2 
[84-85].  Interestingly, we have evidence suggesting that ANRIL may be differentially 
expressed in in vitro models of β-cell dysfunction (our unpublished data). 
In recent years, GWAS have identified many other common genetic variants 
associated with complex diseases such as coronary artery disease, hypertension, T2D and 
others [86]. Interestingly, the majority of these variations occurs in non-coding and 
intergenic regions [87] including those associated with T2D. Amongst the 40 variants 
 22 
associated with the disease, 19 of them map to intergenic regions that lie at great genomic 
distances from their closest protein coding gene (up to 500kb) [88]. It is becoming clear 
that the majority of these variants could lie into or in the vicinity of LncRNAs and 
therefore affect their proper function or expression. A study by Cabili at al. [77], 
confirmed that a great number of these variants are indeed contained within lincRNAs 
sequences and that the expression of these lincRNAs is specific to the tissues relevant to 
the associated disease.  
Screenings of LncRNAs in β-cells have yet to be performed but it is likely that 
many of them will exhibit β-cell specific expression. Given the tissue specificity of 
LncRNAs and their involvement in multiple cell functions, LncRNAs may be anticipated 
to play a major effect on the maintenance of β-cell functions and could therefore be 
implicated in diabetes pathogenesis.  
 
Conclusion 
The unexpected discovery of the existence of a multitude of non-coding RNA molecules 
populating many of the cellular organelles has added a new layer of complexity to the 
mechanisms governing the biological processes in mammalian cells. We are only 
beginning to decipher the properties of these newly discovered RNAs but we have 
already strong indications that they play major regulatory roles in different cellular 
activities. A better understanding of the mode of action of these fascinating molecules 
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Figure 1. Proposed model of cellular localization of microRNAs 
Usually, miRNA biogenesis occurs in the nucleus and is followed by export to the 
cytoplasm (a) and processing to the mature form acting as translational repressor of target 
mRNAs. However, mature miRNAs can also localize to other cellular compartments such 
as nucleus (b), nucleolus (c), p-bodies (d), stress granules (e) and mitochondria (f). In 
addition, some miRNAs have been suggested to be generated inside the mitochondria. 
 
 
Figure 2. Horizontal transfer of microRNAs as an emerging new form of cell-to-cell 
communication. 
After being transcribed in the nucleus and exported in the cytoplasm, miRNAs are 
processed to a mature form. The mature miRNAs can bind to complementary 3’UTR of 
target mRNAs to inhibit translation (a) or can be packaged and released and transferred to 
donor cells by several pathways. Secreted miRNAs can be released in the circulation and 
reach distant cells in a vesicle-associated form or bound to proteins (endocrine transfer) 
(b), can be transferred to adjacent cells (paracrine transfer) (c), or can enter neighbouring 
cells through gap junctions (cell junction transfer) (d). 
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Table 1: Overview of all the microRNAs known to have a functional role in pancreatic 
β-cell development and function. When available, identified and confirmed targets 
are listed for each miRNA.  
 
MicroRNA Known functional effect Targets References 
let-7 insulin secretion  [40] 
miR-7 pancreas development & insulin production   [33] 




miR-15a regulation of insulin synthesis  [43] 
miR-21 insulin secretion 





miR-24 insulin-gene transcription Sox6 [24] 
miR-26 insulin-gene transcription Sox6, Bhlhe22 [24] 
miR-29a,b insulin secretion Mctl1 [37] 
miR-30d insulin-gene transcription  [42] 
miR-33a insulin secretion ABCA1 [38] 
miR-34a insulin secretion 
cytokines-induced apoptosis 
VAMP2, Rab3a [45-46] 
[46] 
miR-96 insulin secretion  Noc2 [36] 






miR-133 insulin biosynthesis PTB [44] 
miR-146a,b cytokines-induced apoptosis  [46] 
miR-148a insulin-gene transcription Sox6 [24] 
miR-182 insulin-gene transcription Bhlhe22 [24] 
miR-200 insulin-gene transcription Sox6, Bhlhe22 [24] 
miR-335 insulin secretion Stxbp1 [41] 
miR-375 insulin-gene transcription 
insulin secretion  
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